Hemorrhagic cystitis (HC) is a common toxicity of preparative regimens for bone marrow transplantation (BMT). Severe HC often requires prolonged and expensive hospitalization, and occasionally can result in death. To investigate the risk factors for severe HC, we conducted a retrospective study among 1908 patients who received BMTs at the University of Minnesota during 1974 to 1993. A previous report from our institution reported on 977 of these patients. We identified all patients with genitourinary complication within 100 days post-BMT from the BMT database. Medical charts for these patients were reviewed to determine whether the patient had HC and also the grade of HC. A total of 208 HC cases were identified during the study period. Of them, 92 patients had severe HC, an incidence of 5% (95% CI = 4-6%). We found that grade II-IV graftversus-host disease (RR = 2.56; 95% CI = 1.43-4.56), use of busulfan (RR = 2.69; 95% CI = 1.35-5.35), and age at transplant (RR = 2.20; 95% CI = 1.27-3.81, for age of 10-30 compared to age of 0-9) were related to an increased risk of HC. In contrast, transplant year was inversely associated with the risk of HC (trend test, P Ͻ 0.01). We did not find any significant difference in HC with the use of prophylactic Mesna. Keywords: bone marrow transplantation; complications; hemorrhagic cystitis; risk factors; adenovirus; cytomegalovirus Outcome after bone marrow transplantation (BMT) has improved over the past 20 years, 1 but preparative regimenrelated toxicities (RRT) remain a major limitation to further progress. Hemorrhagic cystitis (HC) is a common RRT.
inflammation, ulceration, hemorrhage, and necrosis of the urothelium within a few hours. 9 The diagnosis of HC is usually made when hematuria occurs in the absence of urinary tract bacterial infection or generalized hemorrhagic diathesis. 10 Clinical presentation of HC varies from mild limited hematuria and/or dysuria to uncontrollable gross bleeding, urinary obstruction, and acute renal failure. Reported incidence rates of HC post-BMT ranged from 7% to 52%. 11, 12 This rather wide range of estimate is primarily attributable to the disparate definitions of HC used in the literature, ranging from six 11 to greater than 100 13 red blood cells per high power field (RBC/hpf) in the urinalysis. HC is graded as mild, moderate or severe according to degree of pain and hematuria. Although there is an inconsistency in definition of mild and moderate HC, severe cystitis usually includes presence of gross hematuria with clots and occurrence of clinical complications. Severe cystitis has been reported to occur in about 5% of BMT patients (ranging from 0% 9 to 18%). 10, 11 It can be extremely painful and debilitating, requiring prolonged and expensive hospitalizations, and can contribute to death.
14 Numerous therapeutic approaches have been tried to control pain and bleeding but often without success. [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Because of the severity of HC and difficulty in its treatment, maximal efforts have been made to prevent this complication. Sodium 6 mercaptoethane sulfonate (Mesna) is a sulfhydryl compound that binds to acrolein, and therefore prevents urothelial damage. Mesna was prophylactically initiated as part of the preparative regimen for BMT at the University of Minnesota in 1989. We conducted a retrospective study to examine the major risk factors for HC and the impact of prophylactic Mesna. Because of clinical relevance and consistency in the diagnosis between and within institutions, this study focused on severe HC.
Patients and methods
Information on all patients receiving BMT at the University of Minnesota, including sex, age, diagnosis, remission status, conditioning therapy, graft-versus-host disease (GVHD) prophylaxis, and complications of the transplants, is prospectively collected by the BMT database. Patients with any genitourinary complication were first identified from the database files. Using database reports and chart review, HC was graded as mild, moderate, or severe, as previously reported: 14 mild HC was defined as sustained (у7 days) microscopic hematuria; moderate HC was defined by the presence of clots, dysuria or gross hematuria; and severe HC by the presence of complications such as urinary obstruction, renal failure, uncontrollable bleeding requiring bladder irrigation, topical instillations (eg alum and formalin), cauterization, or surgical intervention. In patients with intermittent or recurrent symptoms, the date of onset of HC was defined as the first day of HC symptoms or laboratory evidence appearing post-initiation of the conditioning therapy. The worst clinical presentation was considered as the grade of HC. When severe cystitis was identified, a complete chart review was conducted to gather information on clinical course, interventions, complications and sequelae of the HC. Since availability of data on patient follow-up after day 100 post-BMT depends on communication with the primary physician and on the frequency of the patient visits, only HCs that occurred within 100 days post-BMT were included in this analysis. Data on HC after second transplant were analyzed separately. During the 1 year period (1989) (1990) when Mesna was being incorporated into the preparative regimen protocols, patients receiving CY as part of the preparative regimen for BMT had different methods of urinary prophylaxis. To define whether the patients received Mesna, intravenous hyper-hydration (IVH), or continuous bladder irrigation (CBI), medical charts of all patients transplanted during that interval were reviewed.
Prophylaxis for GVHD included cyclosporin A (CsA), methotrexate (MTX), anti-thymocyte globulin (ATG), steroids, elutriation or other forms of T cell depletion. Conditioning therapy used busulfan, CY, or other chemotherapy alone or combined with total body irradiation (TBI) or total lymphoid irradiation (TLI). CY doses ranged from 20 to 240 mg/kg, administered as a 2-h infusion, over 1 to 4 days, with a maximum of 60 mg/kg/day. Hydration with 3-4 l/m 2 /day started 6-12 h before the first CY infusion and finished 24 h after the last dose. Patients voided every 1-2 h during hydration and furosemide was given as needed to maintain adequate diuresis. Heme dipstick testing was conducted at the bedside two to three times a day for the initial hospitalization. If heme-positive, the urine was sent for microscopic analysis and culture; some heme-positive samples were also sent for electron microscopy to assess for presence of viral particles. Urinalysis and urine cultures were performed at least weekly during hospitalization, and then, at every hospital visit until day 100. Positive results from urine cultures were entered into the database.
Since 1990 all patients receiving CY at doses greater than 60 mg/kg also received Mesna at equal total dose, divided 15 min before and 3, 6, 9 and 12 h after each dose. A few patients received Mesna as an intravenous continuous infusion over 24 h after each dose of CY. The treatment of HC consisted of intravenous hydration and platelet support. Renal and pelvic ultrasound were performed if urinary obstruction was suspected. When clinically indicated, patients were catheterized and the bladder continuously irrigated at 3-5 l/h, titrated to keep a pink outflow. If the bleeding was not controlled, cystoscopy with clot removal and fulguration of the bleeding sites was performed. Other topical therapies included prostaglandins, formalin, alum, aminocaproic acid (amicar) and glutamine.
Statistical analysis
The incidence of HC from initiation of conditioning therapy to day 100 post-BMT was calculated by Kaplan-Meier estimation, censoring at last follow-up, death, or second transplant. Univariate comparisons were performed using Mantel-Cox log-rank test, and Tarone's test for trend. Factors examined in the univariate analysis included sex, transplant type, year of transplant, age, underlying diagnosis, number of remissions, use and dose of CY, use of busulfan, radiation, presence of advanced GVHD (grade II-IV), and positive urine cultures. The Cox proportional hazard model was applied in the multiple regression analysis. The incidence of severe HC in patients with positive urine cultures was calculated by Kaplan-Meier estimation. To assess the incidence of late HC, additional censoring occurred for onset of HC prior to day 60. Late HC is defined as onset of HC between days 60 and 100 post-BMT.
Results
From 1974 to 1993, 1908 patients received BMT at the University of Minnesota. Patient characteristics and their association with severe HC are shown in Table 1 .
Forty-one percent were female and 59% male. Half of the patients were children (р19 years), most of them younger than 9 years of age. Forty-five percent of the patients were within the second to fourth decades of life and only 4% were 50 years old or older. Most patients received BMT to treat underlying malignancies: 44% acute leukemia/myelodysplastic syndrome (MDS), 20% chronic myelogenous leukemia (CML), and 21% other malignancies. Other underlying diagnoses were severe aplastic anemia (SAA), immunodeficiencies (ID), and metabolic disorders (MD), accounting for 16% of all patients. Fiftyone percent of patients had allogeneic transplants from related donors (primarily matched sibling donors). Fourteen percent of patients received allogeneic transplants from unrelated donors. The remaining 35% of patients received autologous transplants. Fifteen syngeneic transplants were analyzed as autologous transplants. Sixty-one percent of patients received CY as part of the conditioning therapy in doses Ͻ150 mg/kg; 27% had a total dose у150 mg/kg, and 10% did not receive CY. Within the CY users, 58% received Mesna. Conditioning therapy also included radiation in 81% of the patients, and busulfan in 10%. Fiftytwo percent of patients receiving allogeneic transplants developed significant GVHD (grade II-IV).
HC was diagnosed in 208 patients. In 92 cases HC was severe, an incidence of 5% (95% CI, 4-6%). The median onset of HC was 30 days post conditioning therapy, ranging from 3 to 98, with a mean of 35.6 days. Over the past two decades the overall incidence of HC decreased from 30% (95% CI, 18-42%) to 8% (95% CI, 6-10%) and the incidence of severe cystitis decreased from 15% (95% CI, 5-25%) to 4% (95% CI, 2-6%). The decline in the incidence of HC was most evident in the early 1980s, before Mesna was introduced into BMT practice at our institution (1989) (1990) . The incidence of severe HC according to the type of transplant (autologous, related or unrelated donor) is shown in Table 1 . All types of transplants had a higher incidence of severe HC when they were first introduced into our medical practice. An incidence of severe HC as high as 23% in the earlier years, progressively decreased with all types of transplant to approximately 4% (related, P = 0.05; unrelated donor, P = 0.03; autologous, P = 0.33).
Factors associated with a significantly elevated risk of severe HC from univariate analysis were: age, type of transplant, underlying disease, use of busulfan, and GVHD grade II-IV (Table 1) . Results from the multiple regression analysis, using the model that best fitted the data, are shown in Table 2 . Independent risk factors for the development of severe HC were GVHD grade II-IV (RR 2.56; 95% CI, 1.43-4.56), the use of busulfan (RR 2.69; 95% CI, 0. 35-5.35) , and age at BMT (10-30 years old) compared to age 0-9 (RR 2.20; 95% CI, 0.27-3.81). Transplant year was inversely related to risk of HC (trend test, P Ͻ 0.01). The use of Mesna did not significantly influence occurrence of severe HC (RR = 1.2, 95% CI, 0.5-3.2).
Positive urine culture data are shown in Table 3 . Urine culture was positive for adenovirus in 41 patients, who had the highest incidence of severe HC, 29%, compared to 5% for patients without positive adenovirus culture (P Ͻ 0.01). Patients with positive urine cultures for cytomegalovirus and bacteria also had a higher incidence of severe HC, 9% (P Ͻ 0.01) and 6% (P = 0.03), respectively. There were very few late events (six events after day 60); however, later onset HC was associated with positive virus identification.
One hundred and eleven patients received a second BMT at day 28 to 3634 days, mean 535 days after the first transplant. Mild or moderate HC was diagnosed in three patients after the first transplant, 15 patients after the second BMT, and only one patient developed HC after both transplants. No severe HC was diagnosed.
Two subgroups of patients were individually reviewed: four patients with Down's syndrome received BMT and none of them developed HC. Among 12 patients transplanted for adrenoleukodystrophy (ALD) seven developed HC, five of them severe.
Most patients were treated with continuous bladder irrigation (70%) or cystoscopy with clot evacuation and fulguration of the bleeding sites (38%). Other treatments were instillation of alum (14%) or formalin (7%), systemic amicar (23%), prostaglandins (7%), and estrogens (2%). Most patients received a combination of treatment modalities. The complications of the severe cystitis within 100 days post-BMT were urinary obstruction (21%), acute renal failure (21%) with need of dialysis in half of the cases, hydronephrosis (10%), and death in five patients (5%) ( Table 4) .
Discussion
Our decision to focus this study on severe HC was based both on its clinical relevance, and on the accuracy of the diagnosis. Severe HC is a rare but potentially devastating complication of BMT, which causes pain, prolonged hospitalization, and significantly increases cost of transplants. 2, 14, [26] [27] [28] Although HC can be secondary to a variety of factors (drugs, radiation, infections), HC in the BMT setting is usually either related to the use of CY or, later in the course of the transplant, to viral infections. [2] [3] [4] [5] [6] [7] [8] 14 CY has been widely used for conditioning patients for BMT. Methods commonly used for prophylaxis of HC in BMT patients are intravenous hyperhydration (IVH), continuous bladder irrigation (CBI) and, more recently Mesna. 29, 30 Each of these prophylaxes has side-effects: IVH can precipitate fluid overload, congestive heart failure, electrolyte imbalances, especially when associated with CY-induced anti-diuresis. 13, 30 CBI is associated with a higher incidence of microscopic hematuria, is uncomfortable, and is very difficult to use in the pediatric population. Mesna (6 mercaptoethane sodium sulfonate, a sulfhydryl-containing compound) has comparatively fewer side-effects. In our study, we found that the incidence of severe HC progressively decreased over time (trend test, P Ͻ 0.01). This decrease, however, could not be attributed to Mesna use, since the decline in incidence started before Mesna was introduced, and in multiple regression analyses Mesna was not found to have a superior effect in preventing severe HC. Our finding is consistent with earlier clinical trials which demonstrated no difference in efficacy of preventing HC by various prophylactic methods. 11, 30 We did not observe an increase in graft failure rate after introduction of Mesna into our program (data not shown), although some authors have suggested that Mesna might increase the risk of graft failure. 13 The incidence of severe HC for all types of transplant, ie autologous, sibling donor and unrelated donors, was high when the treatment modalities were first introduced into 39 Table 4 Complications of severe hemorrhagic cystitis clinical practice, and subsequently declined. Such a pattern is probably related to patient selection. It is known that the incidence of RRT is directly related to aggressiveness of the disease and to the time from diagnosis. 31 It is common practice that new treatment modalities are initially performed in patients with more aggressive diseases, and accordingly associated with a higher risk of RRT. Additional risk factors for severe HC identified from this study are use of busulfan, presence of GVHD, and age at transplantation (10-30 years of age compared to age under 10), consistent with some earlier reports. 14, [31] [32] [33] It is unclear, however, whether GVHD per se can manifest as HC, 34 or whether GVHD-related immunosuppressive therapies increase the chances of opportunistic infections 35 and subsequently cause HC. Notably, patients with ALD had an unusually high risk of severe HC (five out of 12 transplants), suggesting this group of patients may have an abnormal sensitivity to the chemotherapy. Some patients with severe HC had positive urine cultures for viruses as previously reported. 7, 36, 37 CMV was also more frequently found in the urine of patients with HC.
In summary, our study demonstrated a decreasing incidence of severe HC over the past 20 years. Prophylactic use of Mesna was not a significant factor in this decreased incidence. Patients with certain characteristics, such as older age, use of busulfan, CML and GVHD, have a high risk of developing severe HC.
